
Jazz Pharmaceuticals appoints Renée Galá as CEO to lead next phase of growth
Ella Day | July 16, 2025 | Appointment | Research and Development | CEO, Corporate, Neurology, Oncology, jazz pharmaceuticals, neurology, neuroscience
Jazz Pharmaceuticals has named Renée Galá as its next chief executive officer (CEO), effective 11 August 2025. Galá, currently president and chief operating officer (COO), succeeds co-founder Bruce Cozadd, who will retire as CEO and continue as chairperson of the board.
The appointment follows a thorough succession process led by the board. Galá brings more than 30 years of experience across finance, strategy, corporate development and commercial operations. Since joining Jazz as chief financial officer in 2020 and later serving as president and COO, she has played a central role in reforming the company’s portfolio and driving nearly 90% of revenue growth.
“The board’s priority was to find an exceptional leader who could not only operate the business but also serve as a catalyst in driving long-term growth at this important moment for the company,” said Rick Winningham, lead independent director. “Renée was the clear standout.”
Galá commented: “I look forward to continuing the important efforts underway and working with our team to pursue new opportunities – both within our portfolio and through external innovation.”
Cozadd, who co-founded the company 22 years ago, added: “In her role as Jazz’s CFO and then as our president and COO, Renée’s leadership has been critical.”
Galá will now lead Jazz’s next phase of growth, building on its expanding pipeline and commercial operations.
Ella Day
16/7/25

This article featured in: August 2025 – The Pharmafile Brief
Related Content

Esaote presents new MRI system to support brain glioma surgeries
Gliomas are among the most common primary malignant brain tumours

Johnson & Johnson submits FDA application for Caplyta to prevent schizophrenia relapse
Johnson & Johnson has submitted a supplemental New Drug Application to the US Food and …

Abbvie acquires Cerevel Therapeutics
Abbvie has announced the acquisition of Cerevel Therapeutics, strengthening its neuroscience pipeline. Cerevel has multiple …






